Načítá se...
OR31-1 Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk of Diabetic Ketoacidosis: Clinical and Biochemical Characteristics of 21 Cases
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i’s) are the newest class of anti-hyperglycemic drugs. Their mechanism of action involves increasing urinary glucose excretion by preventing glucose reabsorption in the proximal renal tubules, yet they can also promote ketogenesis under cer...
Uloženo v:
| Vydáno v: | J Endocr Soc |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Endocrine Society
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6554857/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-OR31-1 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|